title: What does the future hold for cell-based tolerogenic therapy?
abstract: Evidence from animal models has shown that the transfer of regulatory T cells or tolerogenic dendritic cells can prevent or cure transplant rejection or re-establish self-tolerance in autoimmune disease. The potential of these tolerogenic cells for the treatment of T-cell-mediated diseases in humans has gained momentum in recent years. Here, Nature Reviews Immunology asks four leading researchers to provide their view on the future of cell-based tolerogenic therapy and to highlight some important issues that must be considered before this form of immunotherapy can become a reality.
authors.affiliation: Immune Tolerance Network and of the Diabetes Center at the University of California, USA.
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Bluestone
authors.forename: Angus W
authors.initials: AW
authors.lastname: Thomson
authors.forename: Ethan M
authors.initials: EM
authors.lastname: Shevach
authors.forename: Howard L
authors.initials: HL
authors.lastname: Weiner
mesh_terms: D000818:Animals; D001327:Autoimmune Diseases / Q000628:therapy*; D005544:Forecasting; D006801:Humans; D007108:Immune Tolerance / Q000276:immunology*; D016219:Immunotherapy, Adoptive / Q000379:methods*; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*